Investor Presentation

Recent Acquisition Avitide Inc. September 16, 2021 AVITIDE Technology leader that advances and expands our Proteins franchise to address the unique purification needs of gene therapies and other emerging modalities R REPLIGEN INSPIRING ADVANCES IN BIOPROCESSING Strengthens, expands core ligand discovery & development capabilities with highly differentiated tech Gives Repligen a new best-in-class platform for affinity resin development, with gene therapy focus Complements Navigo GmbH partnership (Protein A/mAb, Spike Protein/COVID focus) and provides affinity content to drive future growth of Proteins franchise Rapid discovery engine with industry best lead times = more content and resins on the market Leverages our commercial and operational expertise and brings content to OPUS®; further strengthens our downstream chromatography portfolio including systems 3 AAV resin commercial launches planned for 2021/2022 Expected to add revenues of ~$10M in 2022, with expected growth >50% in 2023 Expected to be accretive to adjusted EPS and operating margin in 2023 $150M purchase price (50/50 cash/stock) with earnouts based on revenue milestones

View entire presentation